Asparagine-linked glycans determine the cytotoxic capacity of eosinophil cationic protein (ECP)

Molecular Immunology

Volumn 55, Issue 3-4, 2013, Pages 372-380

  Rubin, Jenny ^a   Venge, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cytotoxicity; Eosinophil granulocyte; Glycosylation; Granule protein; SELDI TOF MS

Indexed keywords

ASPARAGINE DERIVATIVE; ASPARAGINE LINKED GLYCAN; EOSINOPHIL CATIONIC PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD DONOR; CYTOTOXICITY; DEGLYCOSYLATION; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN MODIFICATION;

ASPARAGINE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EOSINOPHIL CATIONIC PROTEIN; GENETIC VARIATION; GLYCOSYLATION; HUMANS; MOLECULAR WEIGHT; POLYSACCHARIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84877610166     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.03.016     Document Type: Article

References (31)

1. Ackerman S.J., Gleich G.J., Loegering D.A., Richardson B.A., Butterworth A.E. Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of Schistosoma mansoni. American Journal of Tropical Medicine and Hygiene 1985, 34:735-745.
2. Barker R.L., Loegering D.A., Ten R.M., Hamann K.J., Pease L.R., Gleich G.J. Eosinophil cationic protein cDNA. Comparison with other toxic cationic proteins and ribonucleases. Journal of Immunology 1989, 143:952-955.
3. Brooks S.A. Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system. Molecular Biotechnology 2004, 28:241-255.
4. Carreras E., Boix E., Navarro S., Rosenberg H.F., Cuchillo C.M., Nogues M.V. Surface-exposed amino acids of eosinophil cationic protein play a critical role in the inhibition of mammalian cell proliferation. Molecular and Cellular Biochemistry 2005, 272:1-7.
5. Carreras E., Boix E., Rosenberg H.F., Cuchillo C.M., Nogues M.V. Both aromatic and cationic residues contribute to the membrane-lytic and bactericidal activity of eosinophil cationic protein. Biochemistry 2003, 42:6636-6644.
6. Eriksson J., Woschnagg C., Fernvik E., Venge P. A SELDI-TOF MS study of the genetic and post-translational molecular heterogeneity of eosinophil cationic protein. Journal of Leukocyte Biology 2007, 82:1491-1500.
7. Gleich G.J., Loegering D.A., Bell M.P., Checkel J.L., Ackerman S.J., McKean D.J. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:3146-3150.
8. Glimelius I., Rubin J., Fischer M., Molin D., Amini R.M., Venge P., Enblad G. Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines. Experimental Hematology 2011, 39:850-858.
9. Hamann K.J., Ten R.M., Loegering D.A., Jenkins R.B., Heise M.T., Schad C.R., Pease L.R., Gleich G.J., Barker R.L. Structure and chromosome localization of the human eosinophil-derived neurotoxin and eosinophil cationic protein genes: evidence for intronless coding sequences in the ribonuclease gene superfamily. Genomics 1990, 7:535-546.
10. Jonsson U.B., Bystrom J., Stalenheim G., Venge P. Polymorphism of the eosinophil cationic protein-gene is related to the expression of allergic symptoms. Clinical and Experimental Allergy 2002, 32:1092-1095.
11. Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). International Journal of Cancer 1992, 50:177-185.
12. Lehrer R.I., Szklarek D., Barton A., Ganz T., Hamann K.J., Gleich G.J. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. Journal of Immunology 1989, 142:4428-4434.
13. Maeda T., Kitazoe M., Tada H., de L.R., Salomon D.S., Ueda M., Yamada H., Seno M. Growth inhibition of mammalian cells by eosinophil cationic protein. European Journal of Biochemistry 2002, 269:307-316.
14. McLaren D.J., McKean J.R., Olsson I., Venge P., Kay A.B. Morphological studies on the killing of schistosomula of Schistosoma mansoni by human eosinophil and neutrophil cationic proteins in vitro. Parasite Immunology 1981, 3:359-373.
15. Melo R.C., Spencer L.A., Dvorak A.M., Weller P.F. Mechanisms of eosinophil secretion: large vesiculotubular carriers mediate transport and release of granule-derived cytokines and other proteins. Journal of Leukocyte Biology 2008, 83:229-236.
16. Navarro S., Aleu J., Jimenez M., Boix E., Cuchillo C.M., Nogues M.V. The cytotoxicity of eosinophil cationic protein/ribonuclease 3 on eukaryotic cell lines takes place through its aggregation on the cell membrane. Cellular and Molecular Life Sciences 2007, 65:324-337.
17. Navarro S., Boix E., Cuchillo C.M., Nogues M.V. Eosinophil-induced neurotoxicity: the role of eosinophil cationic protein/RNase 3. Journal of Neuroimmunology 2010, 227:60-70.
18. Peterson C.G., Jornvall H., Venge P. Purification and characterization of eosinophil cationic protein from normal human eosinophils. European Journal of Haematology 1988, 40:415-423.
19. Plager D.A., Davis M.D., Andrews A.G., Coenen M.J., George T.J., Gleich G.J., Leiferman K.M. Eosinophil ribonucleases and their cutaneous lesion-forming activity. Journal of Immunology 2009, 183:4013-4020.
20. Rosenberg H.F. Recombinant human eosinophil cationic protein. Ribonuclease activity is not essential for cytotoxicity. Journal of Biological Chemistry 1995, 270:7876-7881.
21. Rosenberg H.F., Ackerman S.J., Tenen D.G. Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. Journal of Experimental Medicine 1989, 170:163-176.
22. Rosenberg H.F., Tiffany H.L. Characterization of the eosinophil granule proteins recognized by the activation-specific antibody EG2. Journal of Leukocyte Biology 1994, 56:502-506.
23. Rubin J., Zagai U., Blom K., Trulson A., Engstrom A., Venge P. The coding ECP 434(G>C) gene polymorphism determines the cytotoxicity of ECP but has minor effects on fibroblast-mediated gel contraction and no effect on RNase activity. Journal of Immunology 2009, 183:445-451.
24. Singh A., Batra J.K. Role of unique basic residues in cytotoxic, antibacterial and antiparasitic activities of human eosinophil cationic protein. Biological Chemistry 2011, 392:337-346.
25. Tiffany H.L., Li F., Rosenberg H.F. Hyperglycosylation of eosinophil ribonucleases in a promyelocytic leukemia cell line and in differentiated peripheral blood progenitor cells. Journal of Leukocyte Biology 1995, 58:49-54.
26. Torrent M., de la Torre B.G., Nogues V.M., Andreu D., Boix E. Bactericidal and membrane disruption activities of the eosinophil cationic protein are largely retained in an N-terminal fragment. Biochemical Journal 2009, 421:425-434.
27. Trulson A., Bystrom J., Engstrom A., Larsson R., Venge P. The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clinical and Experimental Allergy 2007, 37:208-218.
28. Winqvist I., Olofsson T., Olsson I. Mechanisms for eosinophil degranulation; release of the eosinophil cationic protein. Immunology 1984, 51:1-8.
29. Woschnagg C., Rubin J., Venge P. Eosinophil cationic protein (ECP) is processed during secretion. Journal of Immunology 2009, 183:3949-3954.
30. Young J.D., Peterson C.G., Venge P., Cohn Z.A. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 1986, 321:613-616.
31. Zhang J., Rosenberg H.F. Sequence variation at two eosinophil-associated ribonuclease loci in humans. Genetics 2000, 156:1949-1958.